{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T08:59:04Z","timestamp":1790499544410,"version":"4.1.0"},"reference-count":104,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1016\/j.autrev.2014.12.002","type":"journal-article","created":{"date-parts":[[2014,12,11]],"date-time":"2014-12-11T12:04:39Z","timestamp":1418299479000},"page":"323-331","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":83,"title":["A comprehensive analysis of treatment outcomes in patients with pemphigus vulgaris treated with rituximab"],"prefix":"10.1016","volume":"14","author":[{"given":"A. Razzaque","family":"Ahmed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn","family":"Shetty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.autrev.2014.12.002_bb0005","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.autrev.2004.05.002","article-title":"The immunogenetics of pemphigus vulgaris","volume":"4","author":"Gazit","year":"2005","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.12.002_bb0010","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.autrev.2011.05.017","article-title":"Autoimmune blistering diseases of the skin","volume":"11","author":"Sticherling","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.12.002_bb0015","doi-asserted-by":"crossref","first-page":"A379","DOI":"10.1016\/j.autrev.2009.10.009","article-title":"Geoepidemiologic considerations of auto-immune pemphigus","volume":"9","author":"Meyer","year":"2010","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.12.002_bb0020","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/S1568-9972(03)00035-1","article-title":"T-cellular autoimmunity against desmogleins in pemphigus, an autoantibody-mediated bullous disorder of the skin","volume":"2","author":"Hertl","year":"2003","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.12.002_bb0025","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.autrev.2008.07.021","article-title":"Pemphigus and infectious agents","volume":"8","author":"Sagi","year":"2008","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.12.002_bb0030","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S1568-9972(02)00056-3","article-title":"Autoreactive T cell responses in pemphigus and pemphigoid","volume":"1","author":"Oostingh","year":"2002","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.12.002_bb0035","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0140-6736(05)66829-8","article-title":"Pemphigus","volume":"336","author":"Bystryn","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2014.12.002_bb0040","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/j.1365-4632.2004.02501.x","article-title":"Pemphigus: analysis of 1209 cases","volume":"44","author":"Chams-Davatchi","year":"2005","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.autrev.2014.12.002_bb0045","first-page":"CD006263","article-title":"Interventions for pemphigus vulgaris and pemphigus foliaceus","author":"Martin","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.autrev.2014.12.002_bb0050","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.jaad.2010.04.039","article-title":"A systematic review of randomized controlled trials for pemphigus vulgaris and pemphigus foliaceus","volume":"64","author":"Martin","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2014.12.002_bb0055","doi-asserted-by":"crossref","first-page":"32","DOI":"10.12703\/P6-32","article-title":"Management of pemphigus","volume":"6","author":"Daniel","year":"2014","journal-title":"F1000Prime Rep"},{"key":"10.1016\/j.autrev.2014.12.002_bb0060","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.clindermatol.2011.03.013","article-title":"Immunosuppressive therapy for autoimmune bullous diseases","volume":"30","author":"Meurer","year":"2012","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.autrev.2014.12.002_bb0065","first-page":"391","article-title":"Drug therapy of pemphigus vulgaris","volume":"l42","author":"Ahmed","year":"2007","journal-title":"G Ital Dermatol Venereol"},{"key":"10.1016\/j.autrev.2014.12.002_bb0070","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.clindermatol.2011.03.014","article-title":"Current therapy of the pemphigus group","volume":"30","author":"Kasperkiewicz","year":"2012","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.autrev.2014.12.002_bb0075","first-page":"622","article-title":"Where does rituximab fit in the treatment of autoimmune mucocutaneous blistering skin disease?","volume":"11","author":"Nigam","year":"2012","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.autrev.2014.12.002_bb0080","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2165\/00128071-200506050-00006","article-title":"Treatment of pemphigus vulgaris: current and emerging options","volume":"6","author":"Yeh","year":"2005","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.autrev.2014.12.002_bb0085","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.autrev.2005.04.004","article-title":"CD20: a target antigen for immunotherapy of autoimmune diseases","volume":"4","author":"Perosa","year":"2005","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.12.002_bb0090","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.autrev.2009.08.007","article-title":"Current status on B-cell depletion therapy in autoimmune diseases other than rheumatoid arthritis","volume":"9","author":"D\u00f6rner","year":"2009","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.12.002_bb0095","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.autrev.2009.02.003","article-title":"B-cell depletion in autoimmune diseases. Advances in autoimmunity","volume":"8","author":"Guzman Moreno","year":"2009","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.12.002_bb0100","first-page":"66","article-title":"Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma","volume":"26","author":"Grillo-L\u00f3pez","year":"1999","journal-title":"Semin Oncol"},{"key":"10.1016\/j.autrev.2014.12.002_bb0105","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1136\/ard.2006.061002","article-title":"Consensus statement on the use of rituximab in patients with rheumatoid arthritis","volume":"66","author":"Smolen","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2014.12.002_bb0110","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1586\/eci.11.22","article-title":"Relevance of rituximab therapy in pemphigus vulgaris: analysis of current data and the immunologic basis for its observed responses","volume":"7","author":"Feldman","year":"2011","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.autrev.2014.12.002_bb0115","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.jaad.2008.01.012","article-title":"Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus","volume":"58","author":"Murrell","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2014.12.002_bb0120","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.autrev.2014.01.011","article-title":"Diagnosis and classification of pemphigus and bullous pemphigoid","volume":"13","author":"Kershenovich","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.12.002_bb0125","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.autrev.2014.01.047","article-title":"Diagnosis and classification of autoimmune blistering diseases","volume":"13","author":"Baum","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.12.002_bb0130","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.autrev.2010.08.007","article-title":"Modern diagnosis of autoimmune blistering skin diseases","volume":"10","author":"Schmidt","year":"2010","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.12.002_bb0135","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa067752","article-title":"A single cycle of rituximab for the treatment of severe pemphigus","volume":"357","author":"Joly","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2014.12.002_bb0140","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1001\/archderm.143.8.1033","article-title":"Treatment of severe pemphigus with rituximab: report of 12 cases and a review of the literature","volume":"143","author":"Cianchini","year":"2007","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.autrev.2014.12.002_bb0145","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1080\/09546630701286110","article-title":"Treatment of refractory pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab): five cases","volume":"18","author":"Antonucci","year":"2007","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.autrev.2014.12.002_bb0150","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1038\/jid.2009.27","article-title":"Rituximab mediates a strong elevation of B-cell-activating factor associated with increased pathogen-specific IgG but not autoantibodies in pemphigus vulgaris","volume":"129","author":"Nagel","year":"2009","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2014.12.002_bb0155","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1038\/jid.2008.172","article-title":"Rituximab exerts a dual effect in pemphigus vulgaris","volume":"128","author":"Eming","year":"2008","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2014.12.002_bb0160","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.clim.2009.05.007","article-title":"Immunogenicity of rituximab in patients with severe pemphigus","volume":"132","author":"Schmidt","year":"2009","journal-title":"Clin Immunol"},{"key":"10.1016\/j.autrev.2014.12.002_bb0165","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/j.1365-2133.2007.07800.x","article-title":"Rituximab in the adjuvant treatment of pemphigus vulgaris: a prospective open-label pilot study in five patients","volume":"156","author":"Goh","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2014.12.002_bb0170","doi-asserted-by":"crossref","first-page":"321950","DOI":"10.1155\/2010\/321950","article-title":"Targeted immunotherapy with rituximab leads to a transient alteration of the IgG autoantibody profile in pemphigus vulgaris","volume":"2010","author":"M\u00fcller","year":"2010","journal-title":"Dermatol Res Pract"},{"key":"10.1016\/j.autrev.2014.12.002_bb0175","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.jaad.2011.12.019","article-title":"Rituximab treatment of severe pemphigus: long-term results including immunologic follow-up","volume":"67","author":"Reguiai","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2014.12.002_bb0180","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1159\/000332848","article-title":"Long-term prognosis of pemphigus in Korea: retrospective analysis of 199 patients","volume":"223","author":"Kim","year":"2011","journal-title":"Dermatology"},{"key":"10.1016\/j.autrev.2014.12.002_bb0185","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1159\/000357031","article-title":"Pilot study of 19 patients with severe pemphigus: prophylactic treatment with rituximab does not appear to be beneficial","volume":"228","author":"Gregoriou","year":"2014","journal-title":"Dermatology"},{"key":"10.1016\/j.autrev.2014.12.002_bb0190","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1001\/archdermatol.2012.1522","article-title":"Adjuvant rituximab therapy of pemphigus: a single-center experience with 31 patients","volume":"148","author":"Lunardon","year":"2012","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.autrev.2014.12.002_bb0195","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1159\/000187431","article-title":"Clinical and immunological follow-up of pemphigus patients on adjuvant treatment with immunoadsorption or rituximab","volume":"218","author":"Pf\u00fctze","year":"2009","journal-title":"Dermatology"},{"key":"10.1016\/j.autrev.2014.12.002_bb0200","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/j.1365-4632.2012.5847.x","article-title":"Adjuvant rituximab in the treatment of pemphigus vulgaris: a phase II clinical trial","volume":"52","author":"Balighi","year":"2013","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.autrev.2014.12.002_bb0205","doi-asserted-by":"crossref","first-page":"175ra30","DOI":"10.1126\/scitranslmed.3005166","article-title":"Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell response","volume":"5","author":"Colliou","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.autrev.2014.12.002_bb0210","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1067\/mjd.2002.126273","article-title":"Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder","volume":"47","author":"Salopek","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2014.12.002_bb0215","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1046\/j.1365-2230.2003.01283.x","article-title":"Treatment of resistant pemphigus vulgaris with an anti-CD20 monoclonal antibody (Rituximab)","volume":"28","author":"Cooper","year":"2003","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.autrev.2014.12.002_bb0220","first-page":"ELT24","article-title":"Anti-CD20 monoclonal antibody (rituximab) in the treatment of autoimmune diseases. Successful result in refractory pemphigus vulgaris: report of a case","volume":"88","author":"Virgolini","year":"2003","journal-title":"Haematologica"},{"key":"10.1016\/j.autrev.2014.12.002_bb0225","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1046\/j.1365-2133.2003.05209_10.x","article-title":"Treatment of pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab)","volume":"148","author":"Herrmann","year":"2003","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2014.12.002_bb0230","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.jaad.2003.08.021","article-title":"Long-term complete remission of severe pemphigus vulgaris with monoclonal anti-CD20 antibody therapy and immunophenotype correlations","volume":"50","author":"Espa\u00f1a","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2014.12.002_bb0235","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.jaad.2004.06.007","article-title":"Therapy of refractory pemphigus vulgaris with monoclonal anti-CD20 antibody (rituximab)","volume":"51","author":"Morrison","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2014.12.002_bb0240","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1001\/archderm.140.1.91","article-title":"Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody)","volume":"140","author":"Dupuy","year":"2004","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.autrev.2014.12.002_bb0245","first-page":"185","article-title":"Successful rituximab treatment of severe pemphigus vulgaris resistant to multiple immunosuppressants","volume":"85","author":"Wenzel","year":"2005","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.autrev.2014.12.002_bb0250","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/j.1365-2133.2005.06651.x","article-title":"Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus","volume":"153","author":"Arin","year":"2005","journal-title":"Br J Dermatol"},{"issue":"10","key":"10.1016\/j.autrev.2014.12.002_bb0255","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/j.1346-8138.2005.tb00862.x","article-title":"Severe pemphigus vulgaris treated with rituximab (Mabthera)","volume":"32","author":"Cecchi","year":"2005","journal-title":"J Dermatol"},{"key":"10.1016\/j.autrev.2014.12.002_bb0260","first-page":"266","article-title":"Delayed response of oral pemphigus vulgaris to rituximab treatment","volume":"16","author":"Niedermeier","year":"2006","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.autrev.2014.12.002_bb0265","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1111\/j.1365-2133.2007.08189.x","article-title":"Late-onset neutropenia following rituximab treatment in patients with autoimmune diseases","volume":"157","author":"Rios-Fern\u00e1ndez","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2014.12.002_bb0270","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2340\/00015555-0007","article-title":"Long-lasting remission of pemphigus vulgaris treated with rituximab","volume":"86","author":"Esposito","year":"2006","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.autrev.2014.12.002_bb0275","first-page":"351","article-title":"Treatment of refractory pemphigus with the anti-CD20 monoclonal antibody (rituximab)","volume":"4","author":"Marzano","year":"2008","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.autrev.2014.12.002_bb0280","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1468-3083.2007.02340.x","article-title":"Treatment failure with rituximab in a patient with pemphigus vulgaris","volume":"22","author":"Weger","year":"2008","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.autrev.2014.12.002_bb0285","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3315\/jdcr.2008.1007","article-title":"Rituximab therapy of recalcitrant bullous dermatoses","volume":"2","author":"Wollina","year":"2008","journal-title":"J Dermatol Case Rep"},{"issue":"Suppl. 1","key":"10.1016\/j.autrev.2014.12.002_bb0290","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1111\/j.1529-8019.2008.00194.x","article-title":"Rituximab in refractory pemphigus vulgaris","volume":"21","author":"Sorce","year":"2008","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.autrev.2014.12.002_bb0295","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.jbspin.2007.10.010","article-title":"Polymyositis and pemphigus vulgaris in a patient: successful treatment with rituximab","volume":"75","author":"Tournadre","year":"2008","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.autrev.2014.12.002_bb0300","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/j.1365-4632.2009.04192.x","article-title":"Pemphigus vulgaris\u2014still a difficult disease to treat","volume":"49","author":"Menezes","year":"2010","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.autrev.2014.12.002_bb0305","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/j.1365-2133.2005.06740.x","article-title":"Long-standing remission of recalcitrant juvenile pemphigus vulgaris after adjuvant therapy with rituximab","volume":"153","author":"Schmidt","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2014.12.002_bb0310","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1590\/abd1806-4841.20131905","article-title":"Off-label use of rituximab in dermatology: pemphigus treatment","volume":"88","author":"Bomm","year":"2013","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.autrev.2014.12.002_bb0315","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1016\/j.jaad.2012.12.967","article-title":"Successful single-cycle rituximab treatment in a patient with pemphigus vulgaris and squamous cell carcinoma of the tongue and IgG antibodies to desmocollins","volume":"69","author":"Kim","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2014.12.002_bb0320","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1590\/abd1806-4841.20131990","article-title":"Severe multi-resistant pemphigus vulgaris: prolonged remission with a single cycle of rituximab","volume":"88","author":"Corral","year":"2013","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.autrev.2014.12.002_bb0325","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000287254","article-title":"Rituximab in childhood pemphigus vulgaris: a long-term follow-up case and review of the literature","volume":"221","author":"Fuertes","year":"2010","journal-title":"Dermatology"},{"key":"10.1016\/j.autrev.2014.12.002_bb0330","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1365-2133.2006.07646.x","article-title":"Rituximab in autoimmune bullous diseases: mixed responses and adverse effects","volume":"156","author":"Schmidt","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2014.12.002_bb0335","doi-asserted-by":"crossref","DOI":"10.1111\/jdv.12536","article-title":"Pemphigus vulgaris of the epiglottis successfully treated with rituximab","author":"Gregoriou","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.autrev.2014.12.002_bb0340","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.jaad.2010.07.032","article-title":"Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients","volume":"65","author":"Kasperkiewicz","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2014.12.002_bb0345","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.1365-2133.2011.10663.x","article-title":"Low-dose rituximab is effective in pemphigus","volume":"166","author":"Horv\u00e1th","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2014.12.002_bb0350","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1111\/j.1468-3083.2011.04391.x","article-title":"Efficacy and safety of rituximab treatment in Indian pemphigus patients","volume":"27","author":"Kanwar","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.autrev.2014.12.002_bb0355","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1001\/archdermatol.2011.3320","article-title":"Effect of a single-cycle alternative dosing regimen for rituximab for recalcitrant pemphigus: a case series of 9 patients","volume":"148","author":"Matsukura","year":"2012","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.autrev.2014.12.002_bb0360","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.jaad.2011.11.007","article-title":"Therapy with rituximab for autoimmune pemphigus: results from a single-center observational study on 42 cases with long-term follow-up","volume":"67","author":"Cianchini","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2014.12.002_bb0365","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/j.1365-2133.2011.10585.x","article-title":"Treatment of severe pemphigus with a combination of immunoadsorption, rituximab, pulsed dexamethasone and azathioprine\/mycophenolate mofetil: a pilot study of 23 patients","volume":"166","author":"Kasperkiewicz","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2014.12.002_bb0370","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/j.1365-2133.2011.10732.x","article-title":"Combined treatment with immunoadsorption and rituximab leads to fast and prolonged clinical remission in difficult-to-treat pemphigus vulgaris","volume":"166","author":"Behzad","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2014.12.002_bb0375","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1111\/bjd.12972","article-title":"Clinical and immunological outcomes of high- and low-dose rituximab treatments in patients with pemphigus: a randomized, comparative, observer-blinded study","volume":"170","author":"Kanwar","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2014.12.002_bb0380","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1001\/jamadermatol.2013.6739","article-title":"Durable remission of pemphigus with a fixed-dose rituximab protocol","volume":"150","author":"Heelan","year":"2014","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.autrev.2014.12.002_bb0385","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/jdv.12080","article-title":"Clinical experiences of different dosing schedules of rituximab in pemphigus with various disease severities","volume":"28","author":"Cho","year":"2013","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"10.1016\/j.autrev.2014.12.002_bb0390","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1111\/j.1365-2133.2011.10411.x","article-title":"Clinical efficacy of different doses of rituximab in the treatment of pemphigus: a retrospective study of 27 patients","volume":"165","author":"Kim","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2014.12.002_bb0395","doi-asserted-by":"crossref","first-page":"472","DOI":"10.2340\/00015555-1746","article-title":"First-line combination therapy with rituximab and corticosteroids is effective and safe for pemphigus","volume":"94","author":"Cho","year":"2014","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.autrev.2014.12.002_bb0400","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.jaad.2010.06.033","article-title":"Rituximab used as a first-line single agent in the treatment of pemphigus vulgaris","volume":"65","author":"Craythorne","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2014.12.002_bb0405","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/j.1365-2133.2007.08358.x","article-title":"Treatment of severe pemphigus with protein A immunoadsorption, rituximab and intravenous immunoglobulins","volume":"158","author":"Shimanovich","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2014.12.002_bb0410","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/j.1365-2230.2005.01941.x","article-title":"Response of pemphigus vulgaris to anti-CD20 antibody therapy (rituximab) may be delayed","volume":"31","author":"Belgi","year":"2006","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.autrev.2014.12.002_bb0415","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1080\/09546630701323988","article-title":"Prolonged treatment with rituximab in patients with refractory pemphigus vulgaris","volume":"18","author":"Barrera","year":"2007","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.autrev.2014.12.002_bb0420","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1365-4632.2008.03423.x","article-title":"Two courses of rituximab (anti-CD20 monoclonal antibody) for recalcitrant pemphigus vulgaris","volume":"47","author":"Faurschou","year":"2008","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.autrev.2014.12.002_bb0425","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/j.1600-0714.2011.01017.x","article-title":"Rituximab for the treatment of corticosteroid-refractory pemphigus vulgaris with oral and skin manifestations","volume":"40","author":"Craythorne","year":"2011","journal-title":"J Oral Pathol Med"},{"key":"10.1016\/j.autrev.2014.12.002_bb0430","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1525-1470.2005.00118.x","article-title":"Successful treatment of refractory childhood pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab)","volume":"2","author":"Kong","year":"2005","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.autrev.2014.12.002_bb0435","doi-asserted-by":"crossref","first-page":"632","DOI":"10.4103\/0378-6323.100587","article-title":"Childhood pemphigus vulgaris successfully treated with rituximab","volume":"78","author":"Kanwar","year":"2012","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.autrev.2014.12.002_bb0440","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.autrev.2007.02.010","article-title":"B cells in SLE: different biological drugs for different pathogenic mechanisms","volume":"7","author":"Diamanti","year":"2007","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.12.002_bb0445","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.autrev.2014.08.020","article-title":"The efficacy of novel B cell biologics as the future of SLE treatment: A review","volume":"13","author":"Kamal","year":"2014","journal-title":"Autoimmun Rev."},{"key":"10.1016\/j.autrev.2014.12.002_bb0450","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.autrev.2011.10.023","article-title":"Controversies in rheumatism and autoimmunity","volume":"11","author":"Doria","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.12.002_bb0455","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.autrev.2011.10.013","article-title":"Rituximab\u2014shadow, illusion or light?","volume":"11","author":"van Vollenhoven","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.12.002_bb0460","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.autrev.2012.02.005","article-title":"Rituximab\u2014it was the best of times, it was the worst of times","volume":"11","author":"Isenberg","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.12.002_bb0465","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.autrev.2012.09.002","article-title":"Rituximab-based novel strategies for the treatment of immune-mediated glomerular diseases","volume":"12","author":"Kattah","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.12.002_bb0470","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.autrev.2012.10.020","article-title":"Different effects of biological drugs in rheumatoid arthritis","volume":"12","author":"Atzeni","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.12.002_bb0475","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.autrev.2009.02.008","article-title":"Long term treatment of rheumatoid arthritis with rituximab","volume":"8","author":"Caporali","year":"2009","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.12.002_bb0480","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.autrev.2011.07.005","article-title":"Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literature","volume":"11","author":"Ferri","year":"2011","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.12.002_bb0485","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.autrev.2013.05.004","article-title":"Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab","volume":"12","author":"Berman","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.12.002_bb0490","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.autrev.2011.12.011","article-title":"B-cell directed therapies in antiphospholipid antibody syndrome\u2014new directions based on murine and human data","volume":"11","author":"Khattri","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.12.002_bb0495","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.autrev.2009.01.007","article-title":"Critical analysis of rituximab-induced serological changes in connective tissue diseases","volume":"8","author":"Cornec","year":"2009","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.12.002_bb0500","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.autrev.2014.08.036","article-title":"Profound symptomatic hypogammaglobulinemia: a rare late complication after rituximab treatment for immune thrombocytopenia. Report of 3 cases and systematic review of the literature","volume":"13","author":"Levy","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.12.002_bb0505","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3109\/08916934.2013.838563","article-title":"Preliminary analysis of mortality associated with rituximab use in autoimmune diseases","volume":"46","author":"Shetty","year":"2013","journal-title":"Autoimmunity"},{"key":"10.1016\/j.autrev.2014.12.002_bb0510","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1056\/NEJMoa062930","article-title":"Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin","volume":"355","author":"Ahmed","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2014.12.002_bb0515","first-page":"379","article-title":"Response in patients with pemphigus vulgaris to rituximab therapy. Basis of the biology of B cells","volume":"144","author":"Leuci","year":"2009","journal-title":"G Ital Dermatol Venereol"},{"issue":"Suppl. 3","key":"10.1016\/j.autrev.2014.12.002_bb0520","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1186\/ar1739","article-title":"B cell non-Hodgkin's lymphoma: rituximab safety experience","volume":"7","author":"Mohrbacher","year":"2005","journal-title":"Arthritis Res Ther"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997214002997?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997214002997?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,30]],"date-time":"2023-07-30T15:58:51Z","timestamp":1690732731000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997214002997"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":104,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["S1568997214002997"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2014.12.002","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2015,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A comprehensive analysis of treatment outcomes in patients with pemphigus vulgaris treated with rituximab","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2014.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}